Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 2 · 66.7%High 0 · 0%

Antibody (T cell) vs steroids

Recurrent rejection · kidney transplant recipients: first rejection episode

Antibody (T cell) showed no clear difference in recurrent rejection compared with steroid (stratified by antibody type) (moderate certainty).

1 finding from 1 review

Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 0.75 [0.56, 1]
9 studies · 508 participants
Moderate

Antibody (T cell) + steroid vs steroids

Recurrent rejection · kidney transplant recipients: first rejection episode

Antibody (T cell) + steroid showed no clear difference in recurrent rejection compared with steroid alone (low certainty).

1 finding from 1 review

Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 0.07 [0, 1.06]
1 study · 30 participants
Low

Muromonab‐CD3 (T cell) vs other antibody (stratified by comparator)

Recurrent rejection · kidney transplant recipients: first rejection episode

Muromonab‐CD3 (T cell) showed no clear difference in recurrent rejection compared with other antibody (stratified by comparator) (moderate certainty).

1 finding from 1 review

Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 1.06 [0.59, 1.88]
2 studies · 129 participants
Moderate